Table 3.
Effect of individual single nucleotide polymorphisms on valacyclovir pharmacokinetic parameters in 24 healthy male volunteers
| Cmax (µg ml−1) | AUC0–1.5 h (µg × h/ml) | AUC0–∞ (µg × h/ml) | ||||||
|---|---|---|---|---|---|---|---|---|
| Location | Genotype | n | Mean ± SD | 95% CI of differences | Mean ± SD | 95% CI of differences | Mean ± SD | 95% CI of differences |
| Exon12 (C1236T) | CC | 3 | 2.86 ± 1.44 | 2.41 ± 1.51 | 10.98 ± 3.35 | |||
| CT | 12 | 4.13 ± 1.51 | (−0.48, 3.00) | 3.59 ± 1.43 | (−0.44, 2.79) | 13.82 ± 3.84 | (−1.69, 7.37) | |
| TT | 9 | 3.12 ± 0.86 | (−1.54, 2.05) | 2.71 ± 0.66 | (−1.38, 1.96) | 11.75 ± 2.61 | (−3.91, 5.45) | |
| Exon21 (G2677T/A) | GG | 3 | 2.96 ± 0.37 | 2.81 ± 0.60 | 10.44 ± 1.00** | |||
| GT | 9 | 3.87 ± 1.77 | (−0.97, 2.79) | 3.34 ± 1.54 | (−1.24, 2.30) | 13.20 ± 3.73 | (−1.49, 7.00) | |
| GA | 4 | 3.92 ± 1.07 | (−1.19, 3.12) | 3.20 ± 1.12 | (−1.64, 2.41) | 11.84 ± 2.83** | (−3.47, 6.26) | |
| TT | 4 | 2.92 ± 0.67 | (−2.20, 2.12) | 2.47 ± 0.74 | (−2.37, 1.68) | 11.34 ± 2.32** | (−3.97, 5.76) | |
| TA | 3 | 4.47 ± 1.10 | (−0.80, 3.82) | 3.99 ± 1.36 | (−0.99, 3.35) | 17.45 ± 2.40 | (1.81, 12.20) | |
| AA | 1 | 1.78 | – | 1.51 | – | 9.50 | – | |
| Exon26 (C3435T) | CC | 10 | 3.37 ± 0.95 | 2.88 ± 0.94 | 11.85 ± 2.60 | |||
| CT | 10 | 4.09 ± 1.76 | (−0.53, 1.96) | 3.60 ± 1.56 | (−0.42, 1.86) | 14.08 ± 4.22 | (−0.89, 5.36) | |
| TT | 4 | 2.92 ± 0.67 | (−2.10, 1.19) | 2.47 ± 0.74 | (−1.92, 1.09) | 11.34 ± 2.32 | (−4.64, 3.63) | |
Cmax, peak plasma concentration; AUC0–1.5 h, area under the serum concentration–time curve from time zero to 1.5 h; AUC0–∞, area under serum concentration–time curve from time zero to infinity; n, number of subjects; 95% CI of differences, compared with wild-type groups (1236CC, 2677GG, 3435CC). Data are expressed as arithmetic mean ± standard deviation (SD). **Statistically significant difference (P < 0.05) compared with 2677TA group.